Standardization, Regulation, Quality Assurance and Emerging Technologies in Hemostasis: Issues, Controversies, Benefits, and Limitations

ABSTRACT

There are many benefits to the overall process of standardization for tests of hemostasis and thrombosis. Nevertheless, it should also be recognized there are several specific problems and limitations to this process, as highlighted in this review. Some of the issues are formidable, but it is hoped that they are not insurmountable. Sometimes, clinical pressures drive diagnostic test processes before they are formally proven to be of clinical value. Such clinical pressures drive diagnostic changes in the hemostasis laboratory, including the incorporation of new and emerging technologies, which in turn drives the need for evolving and effective external quality assurance. Incorporated into the diagnostic or test-performance process are a large number of organizations involved in driving standardization, with the ultimate intention of improving diagnostics, but this process will also have unintended potential for adverse outcomes. Although this review notes many of the benefits to the process, it focuses primarily on those negative factors that are often less obvious but still require attention and process review.

Standardization - regulation - laboratory assessments - hemostasis testing - diagnostic practice - quality assurance

REFERENCES

• 1 Cunningham M T, Brandt J T, Chandler W L et al.. Quality assurance in hemostasis: the perspective from the College of American Pathologists Proficiency Testing Program.  Semin Thromb Hemost. 2007;  33 250-258
• 2 Favaloro E J, Bonar R. Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.  Semin Thromb Hemost. 2007;  33 235-242
• 3 Jennings I, Kitchen D P, Woods T AL, Kitchen S, Walker I D. Emerging technologies and quality assurance in hemostasis: the perspective from the National External Quality Assurance Program.  Semin Thromb Hemost. 2007;  33 243-249
• 4 Spannagl M, Dick A, Reinauer H. EQA in Germany: between regulatory bodies and patient outcomes.  Semin Thromb Hemost. 2007;  33 259-264
• 5 Mammen J, Nair S C, Srivastava A. External Quality Assessment Scheme for hemostasis in India.  Semin Thromb Hemost. 2007;  33 265-272
• 6 Olson J D, Preston F E, Nichols W L. External Quality Assurance in Thrombosis and Hemostasis (EQATH): an international perspective.  Semin Thromb Hemost. 2007;  33 220-225
• 7 World Health Organization. Available at: http://www.who.int/en/ Accessed November 18, 2006
• 8 World Federation of Hemophilia. Available at: http://www.wfh.org/index.asp?lang=EN Accessed November 18, 2006
• 9 National Institute for Biological Standards and Control. Available at: http://www.nibsc.ac.uk/ Accessed November 18, 2006
• 10 Clinical and Laboratory Standards Institute. Available at: http://www.nccls.org/ Accessed November 18, 2006
• 11 International Society on Thrombosis and Haemostasis. Available at: http://www.med.unc.edu/isth/ Accessed November 17, 2006
• 12 Australian Government Department of Health and Ageing. Available at: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-npaac-index.htm Accessed November 18, 2006
• 13 National Association of Testing Authorities. Available at: http://www.nata.asn.au/ Accessed November 18, 2006
• 14 United States Food and Drug Administration. Available at: http://www.fda.gov/ Accessed November 18, 2006
• 15 Therapeutic Goods Administration. Available at: http://www.tga.gov.au/ Accessed November 18, 2006
• 16 Mammen E F. Preface: laboratory issues in the identification and diagnosis of von Willebrand disease.  Semin Thromb Hemost. 2006;  32 443-444
• 17 Mammen E F. Preface: hereditary von Willebrand disease and acquired von Willebrand Syndrome: clinical manifestations, diagnosis and management.  Semin Thromb Hemost. 2006;  32 553-554
• 18 Favaloro E J. von Willebrand factor (VWF) collagen binding (activity) assay (VWF:CBA) in the diagnosis of von Willebrand's disorder (VWD): a 15-year journey.  Semin Thromb Hemost. 2002;  28 191-202
• 19 Favaloro E J. Laboratory identification of von Willebrand disease: technical and scientific perspectives.  Semin Thromb Hemost. 2006;  32 456-471
• 20 Favaloro E J. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.  Semin Thromb Hemost. 2006;  32 566-576
• 21 Sadler J E, Budde U, Eikenboom J CJ and the Working Party on von Willebrand Disease Classification et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.  J Thromb Haemost. 2006;  4 2103-2114
• 22 Sadler J E. A revised classification of von Willebrand Disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1994;  71 520-525
• 23 Adams M, Ward C, Thom J et al.. Emerging technologies in hemostasis diagnostics: a report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group.  Semin Thromb Hemost. 2007;  33 226-234
• 24 Favaloro E J, Wong R, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thompson P. A multi-laboratory peer-assessment quality assurance program based evaluation of anti-cardiolipin antibody, and beta-2-glycoprotein-1 antibody, testing.  Semin Thromb Hemost. 2005;  31 73-84
• 25 Wong R, Adelstein S, Gillis D, Favaloro E J. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.  Semin Thromb Hemost. 2005;  31 39-48
• 26 Hubbard A R. International biological standards for coagulation factors and inhibitors.  Semin Thromb Hemost. 2007;  33 283-289
• 27 Gallus A. Management options for thrombophilias.  Semin Thromb Hemost. 2005;  31 118-126
• 28 Favaloro E J, Soltani S, McDonald J, Grezchnik E, Easton L. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S and antithrombin deficiency and the potential high risk of a false positive diagnosis.  Lab Hematol. 2005;  11 174-184
• 29 Favaloro E J. More on ‘universal’ versus ‘selected’ screening for thrombophilia: the hidden costs of false-positive diagnosis.  Br J Haematol. 2006;  134 239-240
• 30 Favaloro E J, Orsag I, Bukuya M, McDonald D. A nine-year retrospective assessment of laboratory testing for Activated Protein C Resistance: evolution of a novel approach to thrombophilia investigations.  Pathology. 2002;  34 348-355
• 31 Hayward C, Eikelboom J. Platelet function testing: quality assurance.  Semin Thromb Hemost. 2007;  33 273-282
• 32 ZLB Behring. History of Haemate. Available at: http://www.zlbbehring.com Accessed November 17, 2006
• 33 Plaimauer B, Scheiflinger F. Expression and characterization of recombinant human ADAMTS-13.  Semin Hematol. 2004;  41 24-33